60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
60 Degrees Pharmaceuticals (SXTP) and Can-Fite BioPharma (CANF) will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV on November 23 at 7 p.m. ET. The program, reaching approximately 73 million U.S. homes, will include interviews with both companies' CEOs. Geoffrey Dow from SXTP will discuss their FDA-approved antimalarial drug ARAKODA and plans to expand its use for diseases like babesiosis. Motti Farbstein from Can-Fite will present their oral drug platform targeting oncology and inflammatory diseases, along with updates on their late-stage clinical pipeline.
60 Degrees Pharmaceuticals (SXTP) e Can-Fite BioPharma (CANF) saranno presenti nello show RedChip Small Stocks, Big Money su Bloomberg TV il 23 novembre alle 19:00 ET. Il programma, che raggiunge circa 73 milioni di famiglie statunitensi, includerà interviste con i CEO di entrambe le aziende. Geoffrey Dow di SXTP discuterà del loro farmaco antimalarico approvato dalla FDA, ARAKODA, e dei piani per espandere il suo utilizzo per malattie come la babesiosi. Motti Farbstein di Can-Fite presenterà la loro piattaforma di farmaci orali che mira a malattie oncologiche e infiammatorie, insieme a aggiornamenti sul loro pipeline clinico in fase avanzata.
60 Degrees Pharmaceuticals (SXTP) y Can-Fite BioPharma (CANF) aparecerán en el programa RedChip Small Stocks, Big Money en Bloomberg TV el 23 de noviembre a las 7 p.m. ET. El programa, que llega a aproximadamente 73 millones de hogares en EE. UU., incluirá entrevistas con los CEO de ambas compañías. Geoffrey Dow de SXTP discutirá su medicamento antipalúdico aprobado por la FDA, ARAKODA, y sus planes para ampliar su uso en enfermedades como la babesiosis. Motti Farbstein de Can-Fite presentará su plataforma de medicamentos orales dirigida a la oncología y enfermedades inflamatorias, junto con actualizaciones sobre su pipeline clínico en etapa avanzada.
60 Degrees Pharmaceuticals (SXTP)와 Can-Fite BioPharma (CANF)가 11월 23일 오후 7시 ET에 Bloomberg TV의 RedChip Small Stocks, Big Money 쇼에 등장합니다. 이 프로그램은 약 7300만 가구에 도달하며, 두 회사의 CEO 인터뷰가 포함됩니다. Geoffrey Dow는 SXTP의 FDA 승인 말라리아 치료제 ARAKODA와 babesiosis와 같은 질병에 대한 사용 확대 계획을 논의할 것입니다. Motti Farbstein은 Can-Fite의 항암 및 염증성 질환을 타겟으로 하는 경구 약물 플랫폼과 후기 단계 임상 시험에 대한 업데이트를 발표할 것입니다.
60 Degrees Pharmaceuticals (SXTP) et Can-Fite BioPharma (CANF) seront présentés dans l'émission RedChip Small Stocks, Big Money sur Bloomberg TV le 23 novembre à 19h ET. Le programme, qui touche environ 73 millions de foyers américains, inclura des interviews avec les PDG des deux entreprises. Geoffrey Dow de SXTP discutera de leur médicament antipaludique approuvé par la FDA, ARAKODA, et des projets pour étendre son utilisation à des maladies comme la babesiose. Motti Farbstein de Can-Fite présentera leur plateforme de médicaments oraux ciblant l'oncologie et les maladies inflammatoires, ainsi que des mises à jour sur leur pipeline clinique avancé.
60 Degrees Pharmaceuticals (SXTP) und Can-Fite BioPharma (CANF) werden am 23. November um 19 Uhr ET in der Sendung RedChip Small Stocks, Big Money auf Bloomberg TV zu sehen sein. Das Programm erreicht rund 73 Millionen Haushalte in den USA und umfasst Interviews mit den CEOs beider Unternehmen. Geoffrey Dow von SXTP wird über ihr von der FDA genehmigtes Antimalariamittel ARAKODA sprechen und Pläne zur Erweiterung seines Einsatzes bei Krankheiten wie der Babesiose vorstellen. Motti Farbstein von Can-Fite wird ihre orale Medikamentenplattform zur Bekämpfung von Onkologie und entzündlichen Erkrankungen präsentieren, sowie Aktualisierungen zu ihrem späten klinischen Pipeline geben.
- SXTP has an FDA-approved antimalarial drug (ARAKODA) in their portfolio
- Company plans to expand ARAKODA's indications to additional diseases
- None.
ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
In an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's mission to develop and commercialize new therapies for infectious diseases. He highlights the FDA-approved antimalarial drug ARAKODA® (tafenoquine) and outlines plans to expand its indications to address other diseases, including babesiosis. Dow also emphasizes the company's commitment to addressing unmet medical needs and improving global health outcomes.
Motti Farbstein, CEO of Can-Fite, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's advanced clinical-stage drug development efforts targeting multi-billion-dollar markets in oncology and inflammatory diseases. He provides insights into Can-Fite's innovative oral drug platform and shares updates on their late-stage clinical pipeline, highlighting the potential impact on patient care and significant potential upcoming milestone and royalty payments.
60 Degrees Pharmaceuticals and Can-Fite BioPharma are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of MASH a Phase III trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: https://www.canfite.com/.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip
View the original press release on accesswire.com
FAQ
When will 60 Degrees Pharmaceuticals (SXTP) interview air on Bloomberg TV?
What is 60 Degrees Pharmaceuticals' (SXTP) main FDA-approved product?
What new indications is SXTP exploring for ARAKODA?
